Miniatura

Fitxers

fneur-15-1417831.pdf (288.5 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2024-06-13

Llicència de publicació

cc by (c) Navarro Pérez, María Pilar et al, 2024
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/214947

Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3389/fneur.2024.1417831

Resum

Background: Real-world studies have shown the sustained therapeutic effect and favourable safety profile of OnabotulinumtoxinA (BoNTA) in the long term and up to 4 years of treatment in chronic migraine (CM). This study aims to assess the safety profile and efficacy of BoNTA in CM after 5 years of treatment in a real-life setting. Methods: We performed a retrospective chart review of patients with CM in relation to BoNTA treatment for more than 5 years in 19 Spanish headache clinics. We excluded patients who discontinued treatment due to lack of efficacy or poor tolerability. Results: 489 patients were included [mean age 49, 82.8% women]. The mean age of onset of migraine was 21.8 years; patients had CM with a mean of 6.4 years (20.8% fulfilled the aura criteria). At baseline, patients reported a mean of 24.7 monthly headache days (MHDs) and 15.7 monthly migraine days (MMDs). In relation to effectiveness, the responder rate was 59.1% and the mean reduction in MMDs was 9.4 days (15.7 to 6.3 days; p < 0.001). The MHDs were also reduced by 14.9 days (24.7 to 9.8 days; p < 0.001). Regarding the side effects, 17.5% experienced neck pain, 17.3% headache, 8.5% eyelid ptosis, 7.5% temporal muscle atrophy and 3.2% trapezius muscle atrophy. Furthermore, after longer-term exposure exceeding 5 years, there were no serious adverse events (AE) or treatment discontinuation because of safety or tolerability issues. Conclusion: Treatment with BoNTA led to sustained reductions in migraine frequency, even after long-term exposure exceeding 5 years, with no evidence of new safety concerns.

Matèries

Migranya, Medicina preventiva

Matèries (anglès)

Migraine, Preventive medicine

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

NAVARRO PÉREZ, María pilar, GONZÁLEZ QUINTANILLA, Vicente, MUÑOZ VENDRELL, Albert, MADRIGAL, Elisabet, ALPUENTE, Alicia, LATORRE, Germán, MOLINA, Francis, MONZÓN, María josé, MEDRANO, Vicente, GARCÍA AZORÍN, David, GONZÁLEZ ORIA, Carmen, GAGO VEIGA, Ana beatriz, VELASCO, Fernando, BELTRÁN, Isabel, MOROLLÓN, Noemí, VIGUERA, Javier, CASAS LIMÓN, Javier, RODRÍGUEZ VICO, Jaime, CUADRADO, Elisa, IRIMIA, Pablo, IGLESIAS, Fernando, GUERRERO PERAL, Ángel luis, BELVÍS, Robert, POZO ROSICH, Patricia, PASCUAL, Julio, SANTOS LASAOSA, Sonia. Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study. _Frontiers in Neurology_. 2024. Vol. 15. [consulta: 23 de gener de 2026]. ISSN: 1664-2295. [Disponible a: https://hdl.handle.net/2445/214947]

Exportar metadades

JSON - METS

Compartir registre